P115 (0048) BRENTUXIMAB VEDOTIN (BV) AS MAINTENANCE OR SALVAGE THERAPY AFTER ASCT FOR RELAPSED/REFRACTORY (R/R) HL

doi: 10.1097/01.HS9.0000547960.36500.e8
Relapsed/Refractory HL
Free

Kameliya Milcheva, Yavor Petrov, Emilia Naseva, Penka Ganeva, Kalina Ignatova, Georgi Aranaudov, Branimir Spasov

no affiliations

Introduction: Brentuximab vedotin (BV) is a chimeric anti-CD30 IgG1 antibody, currently approved for treating classical HL in relapse following either autologous stem cell transplantation (ASCT) or 2 lines of combination chemotherapy in transplant-ineligible patients.High-dose therapy followed by autologous stem-cell transplantation is standard of care for patients with relapsed or primary refractory Hodgkin's lymphoma. Roughly 50% of patients might be cured after autologous stem-cell transplantation; however, most patients with unfavourable risk factors progress after transplantation. Previous data from the AETHERA trial demonstrated increased PFS in patients receiving BV as maintenance therapy following ASCT.

Objective: Evaluate the effectiveness of BV as maintenance or salvage therapy after ASCT for relapsed/refractory (R/R) HL. The primary endpoints included response rate, overall survival, progression-free survival and safety.

Materials and methos: Nine patients with unfavourable-risk relapsed or primary refractory classic Hodgkin's lymphoma who had undergone autologous stem-cell transplantation have been planed to receive 16 cycles of 1·8 mg/kg brentuximab vedotin every 3 weeks, starting 30–45 days after transplantation.

Result: Median age of the patients is 30 years (range 19–64). Median number of courses is 16 (range 5–16). In 5 patients the best response was CR, 1 with SD and 3 progressed. At the and of follow up 3 patients was still in complete response, one's disease was stable disease and 5 have had a progression. Two out of 9 patients had died. Mean survival time of the patients is 68.7 months (95% CI 52.6–84.9), median is not reached (seven out of 9 are still followed up). No significant differences were observed between the stages. Median progression free survival is 49.9 months (median is not reached; 5 cases are still censored). No significant differences were observed between the stages.The most frequent adverse events in the brentuximab vedotin group were peripheral sensory neuropathy.

Conclusion: Early consolidation with brentuximab vedotin after autologous stem-cell transplantation improved progression-free survival in patients with Hodgkin's lymphoma with risk factors for relapse or progression after transplantation. This treatment provides an important therapeutic option for patients undergoing autologous stem-cell transplantation.

Figure

Figure

Figure

Figure

Copyright © 2018 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.